96 related articles for article (PubMed ID: 34142932)
1. Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors.
Lu X; Yan S; Koral KA; Chen Z
Expert Rev Anticancer Ther; 2021 Sep; 21(9):917-926. PubMed ID: 34142932
[No Abstract] [Full Text] [Related]
2. Surufatinib combined with transarterial embolization versus surufatinib monotherapy in patients with liver metastatic neuroendocrine tumors: Study protocol for a prospective, randomized, controlled trial.
Li R; Li X; You X; Su M; Liu Y; Ke N; Cao D
Cancer Med; 2024 Apr; 13(8):e7131. PubMed ID: 38629255
[TBL] [Abstract][Full Text] [Related]
3. Assessing the effectiveness and safety of surufatinib versus everolimus or sunitinib in advanced neuroendocrine neoplasms: insights from a real-world, retrospective cohort study using propensity score and inverse probability treatment weighting analysis.
Zhu L; Ye X; She Y; Liu W; Hasegawa K; Rossi RE; Du Q; Zhai Q
J Gastrointest Oncol; 2024 Apr; 15(2):689-709. PubMed ID: 38756630
[TBL] [Abstract][Full Text] [Related]
4. The Efficacy and Safety of Surufatinib Combined with Anti PD-1 Antibody Toripalimab in Neoadjuvant Treatment of Locally Advanced Differentiated Thyroid Cancer: A Phase II Study.
Chen JY; Huang NS; Wei WJ; Hu JQ; Cao YM; Shen Q; Lu ZW; Wang YL; Wang Y; Ji QH
Ann Surg Oncol; 2023 Nov; 30(12):7172-7180. PubMed ID: 37543550
[TBL] [Abstract][Full Text] [Related]
5. Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
Cives M; Pelle' E; Strosberg J
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33202931
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours - A systematic review and meta-analysis.
Das S; Phillips S; Lee CL; Agarwal R; Bergsland E; Strosberg J; Chan JA; LaFerriere H; Ramirez RA; Berlin J; Dasari A
Eur J Cancer; 2023 Mar; 182():43-52. PubMed ID: 36738541
[TBL] [Abstract][Full Text] [Related]
7. Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib.
Zhang J; Zhu H; Shen L; Li J; Zhang X; Bai C; Zhou Z; Yu X; Li Z; Li E; Yuan X; Lou W; Chi Y; Xu N; Yin Y; Bai Y; Zhang T; Xiu D; Chen J; Qin S; Wang X; Yang Y; Shi H; Luo X; Fan S; Su W; Lu M; Xu J
Chin J Cancer Res; 2023 Oct; 35(5):526-535. PubMed ID: 37969958
[TBL] [Abstract][Full Text] [Related]
8. Surufatinib combined camrelizumab as a valuable third-line rescue therapy for a patient with extensive-stage for small-cell lung cancer: a case report and literature review.
Pan C; Yu T; Han L; Hao D; Yang M; Li L; Chu L; Ni Q
Anticancer Drugs; 2024 Mar; 35(3):271-276. PubMed ID: 37948349
[TBL] [Abstract][Full Text] [Related]
9. Structural basis and selectivity of sulfatinib binding to FGFR and CSF-1R.
Lin Q; Dai S; Qu L; Lin H; Guo M; Wei H; Chen Y; Chen X
Commun Chem; 2024 Jan; 7(1):3. PubMed ID: 38172256
[TBL] [Abstract][Full Text] [Related]
10. Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs).
Xu J
Ther Adv Med Oncol; 2021; 13():17588359211042689. PubMed ID: 34484432
[TBL] [Abstract][Full Text] [Related]
11. Surufatinib-induced renal thrombotic microangiopathy: first case report and review of literature.
Zhu W; Wang W; Shi Y; Shen B; Li Y
Virchows Arch; 2023 Oct; 483(4):561-567. PubMed ID: 37101053
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of surufatinib in the treatment of advanced solid tumors: a systematic evaluation and meta‑analysis.
Cai T; Cheng Y; Du Y; Tan P; Li T; Chen Y; Gao L; Fu W
Oncol Lett; 2023 Jun; 25(6):273. PubMed ID: 37216159
[TBL] [Abstract][Full Text] [Related]
13. A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.
Dasari A; Hamilton EP; Falchook GS; Wang JS; Li D; Sung MW; Chien C; Nanda S; Tucci C; Hahka-Kemppinen M; Paulson AS
Invest New Drugs; 2023 Jun; 41(3):421-430. PubMed ID: 37074571
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of oxaliplatin, surufatinib, and camrelizumab on neuroendocrine carcinoma: a case report and literature review.
Wang X; Hu S; Su F; Lin J; Duan J; Tan H; Tan H
Ann Transl Med; 2022 Nov; 10(22):1254. PubMed ID: 36544653
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and toxicity of surufatinib in neuroendocrine tumors: A systematic review and meta-analysis.
Ali MA; Shah SS; Tahir N; Rehman S; Saeed M; Bajwa SF; Ali R; Aiman W; Anwar MY
J Neuroendocrinol; 2022 Jul; 34(7):e13149. PubMed ID: 35665971
[TBL] [Abstract][Full Text] [Related]
16. Case Report: A rare case of primary paraganglioma of the gallbladder with a literature review.
Xia Y; Wang S; Wang X; Du J; Zhang L; Xia L
Front Oncol; 2022; 12():1031112. PubMed ID: 36776377
[TBL] [Abstract][Full Text] [Related]
17. Corrigendum to 'Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)' [European Journal of Cancer 169 (2022) 1-9].
Li J; Cheng Y; Bai C; Xu J; Shen L; Li J; Zhou Z; Li Z; Chi Y; Yu X; Li E; Xu N; Liu T; Lou W; Bai Y; Yuan X; Wang X; Yuan Y; Chen J; Guan S; Fan S; Su W
Eur J Cancer; 2023 Jan; 178():247-248. PubMed ID: 36402625
[No Abstract] [Full Text] [Related]
18. Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep).
Li J; Cheng Y; Bai C; Xu J; Shen L; Li J; Zhou Z; Li Z; Chi Y; Yu X; Li E; Xu N; Liu T; Lou W; Bai Y; Yuan X; Wang X; Yuan Y; Chen J; Guan S; Fan S; Su W
Eur J Cancer; 2022 Jul; 169():1-9. PubMed ID: 35489301
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]